Phase II Study of Single Agent Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer With No Prior PARP Exposure or Prior PARP Inhibitor Exposure
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- 20 Aug 2012 New trial record
- 18 Aug 2012 Actual end date (Aug 2012) added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.